Four study participants with ALS received a 5-day treatment course with subcutaneous injections of CTLA4-Ig (day 1) simultaneously with low dose IL-2 (days 1–5) every 2 weeks over a 48-week period. This evidence concerns the gene CTLA4 and amyotrophic lateral sclerosis.